Clinical trials: Erythropoietin
Traumatic Optic Neuropathy
Traumatic Optic Neuropathy Treatment Trial (TONTT)
The pathophysiology of Traumatic Optic Neuropathy (TON) is thought to be multifactorial, and some researchers have also postulated a primary and secondary mechanism of injury.TON is categorized as direct or indirect.In indirect…
- Trial name
- TONTT (NCT01783847)
- Testing
- Recombinant human erythropoietin (EPO), Observation, Methyl prednisolone
- Where
- 3 sites in Iran
- Volunteers
- 117 people
- Sponsor
- Tehran University of Medical Sciences
Myelodysplastic Syndrome
Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS
Objectives: Primary: To evaluate the response rate of total cytokine-immunotherapy for low-risk myelodysplastic syndromes (MDS). Secondary: To evaluate response duration, survival and side effects of the treatment.
- Trial name
- NCT00520468
- Testing
- Erythropoietin, Cyclosporin A, G-CSF
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Preterm Infants
Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants
Preterm infants are a risk for multiple transfusions, and the administration of human recombinant erythropoietin (Epo) has been shown to decrease transfusion requirements.
- Trial name
- NCT01235923
- Testing
- three times weekly Epo, weekly Epo
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of New Mexico
Neonatal Anemia
Optimized Erythropoietin (EPO) Treatment
Neonatal anemia is the most commonly encountered hematologic problem among all neonates cared for in the neonatal intensive care unit (NICU).
- Trial name
- OETNA (NCT02075970)
- Testing
- Epoetin Alpha
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Iowa
Anemia, Kidney Diseases
DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)
This is a post-authorisation safety study to assess the incidence and severity of all pre-defined cardiovascular events in patients treated with DYNEPO, as well as to detect \& describe less common adverse drug reactions, and to…
- Conditions
- Anemia, Kidney Diseases, Renal Failure, Chronic, Kidney Failure, Chronic
- Trial name
- DELFT (NCT00664066)
- Testing
- DYNEPO (epoetin delta)
- Where
- 2 sites in Germany
- Volunteers
- 3 people
- Sponsor
- Shire
Infant, Newborn
Darbepoetin Administration to Preterm Infants
Infants born prematurely do not increase production of the primary red cell growth factor, erythropoietin (Epo), and often develop an anemia called the "anemia of prematurity." The anemia of prematurity is the most common anemia…
- Trial name
- NCT00334737
- Testing
- Darbepoetin Alfa Injection, erythropoietin alfa injection
- Where
- 3 sites in United States
- Volunteers
- 102 people
- Sponsor
- University of New Mexico
Leukemia, Myelodysplastic Syndromes
Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00398047
- Testing
- Azacitadine and Hematopoietic Growth Factors
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Wake Forest University Health Sciences
Anemia, Traumatic Brain Injury
Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
The purpose of this study is to determine the effect of early administration of recombinant human erythropoietin on long-term neurological outcome after severe traumatic brain injury.
- Trial name
- NCT00313716
- Testing
- recombinant human erythropoietin, rhEpo
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Claudia Sue Robertson
Multiple Myeloma
Effects of Exercise in Combination With Epoetin Alfa
The purpose of the study was to determine the effect of Epoetin alfa therapy (short term versus long term) with and without a home-based individualized exercise program that incorporated aerobic and strength resistance training…
- Trial name
- NCT00577096
- Testing
- Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Arkansas
Extreme Prematurity
Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)
Recombinant human erythropoietin (Epo) is a promising novel neuroprotective agent. Epo decreases neuronal programmed cell death resulting from brain injury; it has anti-inflammatory effects, increases neurogenesis, and protects…
- Trial name
- PENUT (NCT01378273)
- Testing
- Epo, Control
- Where
- 19 sites in United States
- Volunteers
- 941 people
- Sponsor
- University of Washington
Hypoxic-ischemic Encephalopathy, Neonatal Encephalopathy
Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)
Hypoxic-ischemic encephalopathy (HIE), a condition of reduced blood and oxygen flow to a baby's brain near the time of birth, may cause death or neurologic disability.
- Conditions
- Hypoxic-ischemic Encephalopathy, Neonatal Encephalopathy, Birth Asphyxia
- Trial name
- NEATO (NCT01913340)
- Testing
- Erythropoietin, Normal saline
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Congenital Heart Defect
Erythropoietin and Pediatric Cardiac Surgery
Lack of bloodflow to the heart and brain when the heart is stopped during heart surgery can cause damage to those organs. We hypothesize that a single dose of erythropoietin prior to the heart bypass portion of surgery may…
- Trial name
- EPO (NCT00451698)
- Testing
- acyanotic erythropoietin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medical College of Wisconsin
Cyanotic Congenital Heart Disease, Anemia
Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial
Cyanotic congenital cardiac patients require higher hemoglobin concentrations (red blood cell levels) for optimal oxygen delivery to the body.
- Conditions
- Cyanotic Congenital Heart Disease, Anemia, Cyanosis, Congenital Heart Disease
- Trial name
- NCT02564796
- Testing
- Epoetin Alfa and Iron, Iron
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Diego
Neonatal Encephalopathy, Birth Asphyxia
High-dose Erythropoietin for Asphyxia and Encephalopathy
Hypoxic-ischemic encephalopathy (HIE) occurs when a baby gets reduced blood flow and oxygen to the brain near the time of birth.
- Trial name
- HEAL (NCT02811263)
- Testing
- Erythropoietin
- Where
- 23 sites in United States
- Volunteers
- 500 people
- Sponsor
- University of California, San Francisco
Congenital Heart Disease, Hypoplastic Left Heart Syndrome
Erythropoetin Neuroprotection for Neonatal Cardiac Surgery
Brain problems occur in neonatal open heart surgery with a frequency of 20-70%, seen on neurological examination, brain imaging such as magnetic resonance imaging (MRI), or long term development problems such as learning…
- Conditions
- Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Transposition of the Great Arteries, Aortic Arch Hypoplasia or Interruption
- Trial name
- NCT00513240
- Testing
- Erythropoetin, Normal saline
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Baylor College of Medicine
Leukemia
Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy
The goal of this clinical research study is to learn if Procrit (epoetin alfa) will decrease the need for blood transfusions in patients with Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma (LL), or Burkitt's who are…
- Trial name
- NCT01099202
- Testing
- Procrit (epoetin alfa)
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- M.D. Anderson Cancer Center
Anemia
Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients
A phase 4 clinical investigation in iron-replete pediatric hemodialysis patients, whose legal guardian had provided signed informed consent, and who had satisfied the inclusion and exclusion criteria of the study.
- Trial name
- NCT00224003
- Testing
- Sodium Ferric Gluconate Complex in Sucrose.
- Where
- 10 sites in United States
- Volunteers
- 23 people
- Sponsor
- Watson Pharmaceuticals
Cerebral Palsy
Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy
This randomized control study is aimed to determine efficacy of umbilical cord blood and erythropoietin combination therapy for children with cerebral palsy.
- Trial name
- NCT01193660
- Testing
- Umbilical Cord Blood Infusion, Erythropoietin Injection, Active Rehabilitation
- Where
- South Korea
- Volunteers
- 105 people
- Sponsor
- Sung Kwang Medical Foundation
Breast Cancer
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer.
- Trial name
- NCT00014222
- Testing
- epoetin alfa, filgrastim, cyclophosphamide
- Where
- 78 sites in United States, Canada
- Volunteers
- 2,104 people
- Sponsor
- NCIC Clinical Trials Group
Prematurity
Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin
Approximately 60,000 premature infants are born each year who weigh less than 1,500 grams,many of whom sustain brain damage because of their prematurity.
- Trial name
- BRITE (NCT01207778)
- Where
- 3 sites in United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- University of New Mexico